$3.93 -$0.17 (-4.1%)

04:30 PM EDT on 06/14/19

Amyris Inc Com (NASDAQ:AMRS)

CAPS Rating: 1 out of 5

Current Price $3.93 Mkt Cap $294.8M
Open $4.09 P/E Ratio 0.00
Prev. Close $4.10 Div. (Yield) $0.00 (0.0%)
Daily Range $3.91 - $4.15 Volume 165,409
52-Wk Range $1.87 - $6.05 Avg. Daily Vol. 95

Caps

How do you think NASDAQ:AMRS will perform against the market?

Add Stock to CAPS Watchlist

All Players

84 Outperform
24 Underperform
 

All-Star Players

7 Outperform
12 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top NASDAQ:AMRS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MaxPower13 (99.50)
Submitted March 24, 2014

Just read Maxx's article. http://www.fool.com/investing/general/2014/03/12/can-amyris-inc-save-deep-sea-sharks-and-expand-thi.aspx At this price, I think it's worth taking a shot.

TMFBlacknGold (90.70)
Submitted October 24, 2018

From 8/20/2018:"With the new accounting rule, Amyris has reported year-over-year revenue growth of 19% in the first half of 2018. Without it, revenue would have slipped 27% in the comparable periods. It's something investors need to pay closer… More

NASDAQ:AMRS VS S&P 500 (SPY)

NASDAQ:AMRS Summary

Fools bullish on NASDAQ:AMRS are also bullish on:

Fools bearish on NASDAQ:AMRS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AMRS.

Recs

0
Member Avatar venturecity (< 20) Submitted: 11/12/2018 1:13:50 AM : Outperform Start Price: $6.29 NASDAQ:AMRS Score: -42.27

key ingredient in stevia zero-calorie sweetener can be produced at large scale by Amyris

Recs

2
Member Avatar TMFBlacknGold (90.70) Submitted: 10/24/2018 1:37:44 PM : Underperform Start Price: $5.63 NASDAQ:AMRS Score: +36.58

From 8/20/2018:

"With the new accounting rule, Amyris has reported year-over-year revenue growth of 19% in the first half of 2018. Without it, revenue would have slipped 27% in the comparable periods. It's something investors need to pay closer attention to.

...

On the one hand, revenue reported using ASC 606 is GAAP (the numbers investors should have the most confidence in) and the company is following the accounting principle as written. On the other hand, there's still a significant risk that Amyris is overestimating the royalty revenue that will eventually be received. That might force the company to restate past income statements and adjust them lower while changing how it estimates and accounts for royalty revenue going forward.

Earlier this year, Amyris made a statement that it had uncovered material weaknesses in its financial reporting that might result or might have resulted in numbers being misstated. It remained unresolved as of the end of June 2018. By now, investors probably can guess that the issue centers on ASC 606 and the recognition of royalty revenue. Given all of the complexity, until this can be sorted out I strongly suggest investors stay away from Amyris stock."

https://www.fool.com/investing/2018/08/20/this-synthetic-biology-stock-is-soaring-but-invest.aspx

Recs

0
Member Avatar DCWD40 (27.82) Submitted: 3/15/2018 5:27:54 PM : Outperform Start Price: $6.74 NASDAQ:AMRS Score: -47.14

Company expecting 60% CAGR through 2022. The company is at break even, has top-tier partners for its products, and will be profitable in 2019.

Leaderboard

Find the members with the highest scoring picks in AMRS.

Score Leader

SmallCapRoss

SmallCapRoss (87.07) Score: +220.54

The Score Leader is the player with the highest score across all their picks in AMRS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
EclecticRecluse 78.69 1/31/2011 Underperform 3W $466.80 -99.16% +126.34% +225.49 1 Comment
SmallCapRoss 87.07 1/17/2012 Underperform 5Y $171.60 -97.70% +122.84% +220.54 0 Comment
stratisticalarb 98.14 4/26/2011 Underperform 1Y $398.28 -99.01% +115.05% +214.06 0 Comment
Jeffreyw 25.37 5/15/2012 Underperform 5Y $26.85 -85.33% +115.69% +201.02 0 Comment
rock338xxx < 20 3/27/2012 Underperform 5Y $85.20 -95.38% +104.51% +199.88 0 Comment
VolkOseba 26.43 8/20/2012 Underperform 5Y $56.85 -93.07% +104.16% +197.23 0 Comment
ACMGresearch 40.07 5/10/2013 Underperform 5Y $43.65 -90.97% +77.85% +168.82 0 Comment
rknapton 86.14 7/24/2013 Underperform 5Y $42.30 -90.69% +70.72% +161.41 1 Comment
rbitrage 94.97 10/14/2014 Underperform 5Y $46.95 -91.61% +53.84% +145.45 1 Comment
MMCapitalMgmt 99.93 9/30/2014 Underperform 5Y $59.25 -93.35% +47.13% +140.48 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCowenandCo 75.75 1/3/2014 Underperform NS $72.15 -94.54% +58.22% +152.76 0 Comment
TrackRaymondJame 74.14 2/12/2013 Underperform NS $53.40 -8.71% -0.81% +7.90 2/21/2013 @ $48.75 0 Comment
TrackRSGoodFCF < 20 8/31/2012 Outperform 5Y $46.65 -91.55% +105.44% -196.99 0 Comment
TrackRSGoodFCF < 20 4/19/2012 Outperform 5Y $49.35 +18.20% -4.55% +22.75 6/25/2012 @ $58.33 0 Comment
TrackRSGoodFCF < 20 1/25/2012 Outperform 5Y $153.75 -42.83% +2.70% -45.53 2/22/2012 @ $87.90 0 Comment
TrackDeutscheSec 81.93 9/16/2011 Outperform NS $295.80 -64.83% +10.53% -75.36 2/10/2012 @ $104.03 0 Comment
TrackRWBaird 89.45 7/22/2011 Outperform NS $371.85 -28.08% -8.10% -19.97 11/2/2011 @ $267.45 0 Comment
TrackStifel 90.64 11/8/2010 Outperform NS $260.70 +89.93% +6.33% +83.60 1/28/2011 @ $495.15 0 Comment

Advertisement